Browsing by Author "Saura, Cristina"

Sort by: Order: Results:

  • Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response
    Ciriaco, Nikaoly; Zamora, Esther; Escrivá-de-Romaní, Santiago; Miranda Gómez, Ignacio; Jiménez Flores, José; Saura, Cristina; Sloane, Hillary; Starus, Anna; Fredebohm, Johannes; Georgieva, Lucy; Speight, Graham; Jones, Frederick; Ramón y Cajal, Santiago; Espinosa-Bravo, Martín; Peg, Vicente (SAGE Publications, 2022)
    Background: Although the standard of care is to perform surgery of primary breast cancer (BC) after neoadjuvant chemotherapy (NAC), for certain patients achieving clinical complete response (cCR) and pathologic complete ...
  • GDF15 is an eribulin response biomarker also required for survival of DTP breast cancer cells
    Bellio, Chiara; Emperador, Marta; Castellano, Pol; Gris-Oliver, Albert; Canals, Francesc; Sánchez Pla, Alexandre; Zamora, Esther; Arribas, Joaquín; Saura, Cristina; Serra, Violeta; Tabernero Cartula, Josep; Littlefield, Bruce A.; Villanueva, Josep (MDPI, 2022)
    Drug tolerant persister (DTP) cells enter into a reversible slow-cycling state after drug treatment. We performed proteomic characterization of the breast cancer (BC) DTP cell secretome after eribulin treatment. We showed ...
  • Therapy-induced senescence enhances the efficacy of HER2-targeted antibody-drug conjugates in breast cancer
    Duro-Sánchez, Santiago; Nadal-Serrano, Mercedes; Lalinde-Gutiérrez, Marta; Arenas, Enrique J.; Bernadó Morales, Cristina; Morancho Armisen, Beatriz; Escorihuela, Marta; Pérez-Ramos, Sandra; Escrivá-de-Romaní, Santiago; Gandullo-Sánchez, Lucía; Pandiella, Atanasio; Esteve-Codina, Anna; Rodilla, Verónica; Dijcks,Fred A.; Dokter, Wim H.A.; Cortés, Javier; Saura, Cristina; Arribas, Joaquín (American Association for Cancer Research (AACR), 2022)
    Antibody-drug conjugates (ADC) are antineoplastic agents recently introduced into the antitumor arsenal. T-DM1, a trastuzumab-based ADC that relies on lysosomal processing to release the payload, is approved for HER2-positive ...